SSTR4
SSTR4 (Somatostatin receptor type 4) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.
Overview
Receptor for somatostatin-14. The activity of this receptor is mediated by G proteins which inhibits adenylyl cyclase. It is functionally coupled not only to inhibition of adenylate cyclase, but also to activation of both arachidonate release and mitogen-activated protein (MAP) kinase cascade.
Open Targets scores its association with cancer at 0.57 (direct and indirect evidence; datatypes literature 0.59, clinical 0.90).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · SSTR4 (Somatostatin receptor type 4) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.
- 1 · What it is
SSTR4 (Somatostatin receptor type 4) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.
- 2 · What goes wrong in cancer
Receptor for somatostatin-14. The activity of this receptor is mediated by G proteins which inhibits adenylyl cyclase.
- 3 · How drugs use it
No product in this corpus aims at SSTR4 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:11333 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P31391 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000132671 (association with cancer (MONDO_0004992) 0.57; per-cancer scores at or above 0.5: neuroendocrine neoplasm 0.59 (GraphQL API, CC0))
Biology
Receptor for somatostatin-14. The activity of this receptor is mediated by G proteins which inhibits adenylyl cyclase. It is functionally coupled not only to inhibition of adenylate cyclase, but also to activation of both arachidonate release and mitogen-activated protein (MAP) kinase cascade. Mediates antiproliferative action of somatostatin in tumour cells. Location: Cell membrane (UniProt). Locus 20p11.21 (HGNC).
- Neuroendocrine tumours: Open Targets association 0.59 with neuroendocrine neoplasm (MONDO_0019496)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.96. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"SSTR4" OR ABSTRACT:"SSTR4" OR TITLE:"somatostatin receptor 4" OR ABSTRACT:"somatostatin receptor 4" OR TITLE:"Somatostatin receptor type 4" OR ABSTRACT:"Somatostatin receptor type 4") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SSTR4, not a curated reading list.